Phase I Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 13 Feb 2018 According to the results published in the Journal of Clinical Oncology primary end point (ie, toxicity) of the study was amended from 6 months follow-up to 3 months.
- 13 Feb 2018 Results published in the Journal of Clinical Oncology
- 02 Jan 2018 Status changed from active, no longer recruiting to recruiting.